$18.600
-0.140 (-0.75%)收盘时
BANC 资讯
BANC 事件
Allotera Therapeutics Closes $35M Financing Round
Allotera Therapeutics announced the closing of a $35M financing round comprising equity and venture debt. The company also introduced its new name, Allotera Therapeutics, reflecting its sharpened focus on advancing off-the-shelf CAR-T cell therapies for patients with T-cell cancers . The financing brings Allotera's total capital raised to $150M, building on the company's $115M Series C announced in late 2025. Proceeds will primarily support the ongoing global pivotal T-RRex clinical trial of Soficabtagene Geleucel, also known as Sofi-cel, in relapsed or refractory T-ALL/T-LBL, as well as advance platform capabilities, operational scale-up, and continued team growth. The Series C was led by Fidelity Management & Research Company, with participation from all existing investors. The current extension includes additional participation from Lightchain Capital and BioGenerator, as well as new investors, including Blood Cancer United's Therapy Acceleration Program and others. The venture debt was provided by Banc of California.
JPMorgan Acts as Sole Bookrunner for Deal Range $19.00-$19.15
The deal range was $19.00-$19.15. JPMorgan acted as sole book running manager for the offering.
Banc of California Reports Q1 Revenue of $286.9M
Reports Q revenue $286.9M, consensus $290.57M. Net interest margin expanded 4 basis points to 3.24% compared to fourth quarter 2025, driven by an 11 basis point decline in deposit costs. Report growth in book value per share to $19.80 and tangible book value per share to $17.77, up 9% and 10% year over year, respectively. Jared Wolff, Chairman and CEO of Banc of California, commented, "Our first quarter results reflect disciplined execution and continued strength in our core earnings drivers. We delivered positive operating leverage and significant earnings growth year over year, supported by net interest margin expansion, disciplined expense management, and continued progress in improving the mix and earnings power of the balance sheet. Supported by our healthy capital and liquidity position, we also efficiently deployed capital through opportunistic share repurchases and announced the redemption of subordinated debt. As we look ahead, we are well positioned for continued earnings growth, supported by strong pipelines, embedded asset repricing opportunities, and our attractive market position."
Banc of California Extends Stock Repurchase Program to 2027
Banc of California announced that its Board of Directors approved an extension of the Company's existing stock repurchase program, which was originally announced on March 17, 2025 and subsequently upsized from $150M to $300M on April 23, 2025. Since inception of the program, the Company has repurchased approximately $217M of its common stock, $31M of which was repurchased in 2026, leaving approximately $83 million available for future repurchases. The stock repurchase program, which was previously scheduled to expire in March 2026, has been extended through March 16, 2027. The Company also announced Banc of California's intent to redeem the entire outstanding $385M aggregate principal amount of 3.25% Fixed-to-Floating Rate Subordinated Notes due 2031 originally issued by Pacific Western Bank, which are scheduled to reset to a floating rate equal to three-month term SOFR plus 252 bps beginning on May 1, 2026. The Notes are redeemable in whole or in part beginning on May 1, 2026 at a redemption price equal to 100% of principal amount of the Notes redeemed, plus any accrued and unpaid interest.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。